SAN DIEGO, May 27, 2015 /PRNewswire/ -- Sequenom, Inc.
(NASDAQ: SQNM), a life sciences company committed to enabling
healthier lives through the development of innovative products and
services, today announced that its wholly owned subsidiary,
Sequenom Laboratories, will move its laboratory operations in
Grand Rapids, Michigan to its
facility in Raleigh Durham, North
Carolina. Sequenom Laboratories' cystic fibrosis carrier
screen test will now be performed at the North Carolina laboratory location.
"The expansion of our North
Carolina laboratory operations to include our
HerediT® CF carrier screen test will enable us to
continue to provide high quality and meaningful test offerings to
physicians and their patients while continuing to build value for
our shareholders," said William
Welch, President and Chief Executive Officer of
Sequenom.
Sequenom Laboratories will discontinue its SensiGene®
Fetal RHD Genotyping test as part of the laboratory
consolidation. Test volumes and revenues from the SensiGene
Fetal RHD test historically have not been material to the company's
financial results. Sequenom Laboratories will reintroduce
this test should medical committees issue guidelines that support
broader use and reimbursement of RHD genotyping. Sequenom
will provide transition services and outplacement assistance to
affected employees.
About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is committed to enabling healthier
lives through the development of innovative products and
services. The Company serves patients and physicians by
providing early patient management information. To learn how
Sequenom is interpreting the genome to improve your life, visit
www.sequenom.com.
About Sequenom Laboratories
Sequenom Laboratories™, a CAP-accredited and
CLIA-certified molecular diagnostics laboratory, has developed a
broad range of laboratory tests, with a focus principally on
prenatal care. Branded under the names
HerediT®, HerediT® UNIVERSAL,
MaterniT21® PLUS, NextView™,
SensiGene® and VisibiliT™, these
molecular genetic laboratory-developed tests provide early patient
management information for obstetricians, geneticists, and maternal
fetal medicine specialists. Sequenom Laboratories is changing
the landscape in genetic diagnostics using proprietary cutting edge
technologies. Visit www.laboratories.sequenom.com and follow
@SequenomLabs.
SEQUENOM®, HerediT®,
HerediT® UNIVERSAL, MaterniT21® PLUS,
NextView™, SensiGene®,
VisibiliT™ and Sequenom Laboratories™, are
trademarks of Sequenom, Inc. All other trademarks and service
marks are the property of their respective owners.
Forward-Looking
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements regarding the development of
innovative products and services and the ability to expand the
North Carolina laboratory
location. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements.
Risks are described more fully in the Company's filings
with the Securities and Exchange Commission, including without
limitation the Company's most recent Quarterly Report on Form 10-Q
and other documents subsequently filed with or furnished to the
Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. The Company undertakes no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
Logo - http://photos.prnewswire.com/prnh/20040415/SQNMLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sequenom-laboratories-to-consolidate-michigan-and-north-carolina-facilities-300089580.html
SOURCE Sequenom, Inc.